Chris Meijer

Chris J. L. M. Meijer, M.D., Ph.D.
Chris Meijer received his PhD at VU University medical center Amsterdam and was trained as surgical pathologist at Leiden University Medical center ( LUMC) where he worked as a staff pathologist till 1980. From 1980-1982 he was head of the Department of Immunopathology at the SSDZ, Delft. In 1983 he was appointed as prof.of Pathology and director of the Dept of pathology of the VU-UMC, Amsterdam.
His research is in the field of HPV and cervical cancer.with focus on
the development of molecular techniques for the detection of HPV, development of international guidelines for validation of HPV assays. He was the principle investigator of clinical trials in which was shown that an HPV test protects better against cervical cancer than cytology (POBASCAM), that HPV testing could be used as triage marker for cytological equivocal smears (VUSA-SCREEN), and as test of cure. He also showed that HPV can be used as a screening test in self-collected cervico/vaginal specimen (PROHTECT) and that full molecular cervical screening can be done by HPV testing in combination with methylation marker triage testing.
He is and has been chairman or member of several national and international scientific and strategy committees advising in the field of oncology and pathology and has been awarded for his activities several times by (Inter)national organisations.
Since his retirement in 2010 he leads a research group focussing on the development of a full molecular cervical cancer (self)screening algorithm. In addition he is director of Self-Screen a spin off company from VU UMC which develops and manufactures molecular tests for screening and diagnosis of cervical (pre)cancer